首页> 美国卫生研究院文献>Canadian Journal of Kidney Health and Disease >A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

【2h】

A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

机译：加拿大引入红细胞生成刺激剂随后进入生物制剂治疗慢性肾脏病贫血的预算影响分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundIn Europe, epoetin subsequent entry biologics (SEBs) have been in use since 2007. Canadian patents of erythropoietin stimulating agents are expiring in 2014, therefore it is predicted that epoetin SEBs will penetrate the Canadian market in the near future.

机译：背景技术在欧洲，自从2007年开始使用依泊汀的后续进入生物制剂（SEB）。加拿大促红细胞生成素刺激剂的专利在2014年到期，因此预计依泊汀SEB将在不久的将来进入加拿大市场。

著录项

期刊名称 Canadian Journal of Kidney Health and Disease
作者
Nicole W Tsao; Clifford Lo; Marianna Leung; Judith G Marin; Dan Martinusen;
展开▼
作者单位

展开▼
年(卷),期 2014(1),-1
年度 2014
页码 28
总页数 8
原文格式 PDF
正文语种
中图分类泌尿科学（泌尿生殖系疾病）;小儿泌尿科学;肾疾病;
关键词
Erythropoiesis stimulating agents Epoetin alfa Darbepoetin alfa Subsequent entry biologics Biosimilars Budget impact analysis Economic analysis Health care costs;

机译：促红细胞生成素刺激剂;阿波罗汀（Alpoetin alfa）;达贝泊汀（Darbepoetin alfa）;随后进入的生物制剂;生物仿制药;预算影响分析;经济分析;卫生保健费用;

相似文献

外文文献
中文文献
专利

1. A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada [J] . Nicole W Tsao, Clifford Lo, Marianna Leung, Canadian Journal of Kidney Health and Disease . 2014,第1期

机译：加拿大引入红细胞生成刺激剂随后进入生物制剂治疗慢性肾脏病贫血的预算影响分析
2. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia [J] . Arantes Luiz H. Jr., Crawford Jeffrey, Gascon Pere, Critical reviews in oncology/hematology . 2018,第期

机译：在治疗化疗诱导的贫血和慢性肾病贫血中，快速划分的疗效，安全，经济和健康相关质量结果，致力于和长期的促红细胞生成刺激剂和慢性肾病血症
3. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease [J] . Roberto Robles Nicolas Clinical drug investigation . 2016,第6期

机译：促红细胞生成素治疗慢性肾脏病引起的贫血的安全性
4. Erythropoiesis-stimulating-agent Dose Optimization for Anemia Management in Chronic Kidney Disease using Recursive Constrained Modeling and Zone Model Predictive Control [C] . Jayson McAllister, Jinfeng Liu, Zukui Li, Annual American Control Conference . 2018

机译：递归约束模型和区域模型预测控制用于慢性肾脏病贫血管理的红细胞生成刺激剂剂量优化
5. Utilization patterns and economic impact of IV iron and erythropoiesis stimulating agents in chronic kidney disease patients: A multi-hospital study [D] . Joshi, Avani D. 2010

机译：慢性肾脏病患者静脉输注铁和促红细胞生成素刺激剂的使用模式和经济影响：一项多院研究
6. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents [O] . M. R. Silver, R. Geronemus, M. Krause, -1

机译：Q2W darbepoetin alfa对未接受促红细胞生成素治疗的慢性肾脏病患者的贫血治疗
7. A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada [O] . 2014

机译：加拿大引入红细胞生成刺激剂随后进入生物制剂治疗慢性肾脏病贫血的预算影响分析

A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅